The randomized phase II ANBL1221 trial conducted by the COG compared the combination of irinotecan, temozolomide, and temsirolimumus with irinotecan, temozolomide, and dinutuximab plus GM-CSF in children with relapsed or refractory neuroblastoma (98). The gene discussed is CSF2; the disease is neuroblastoma.